|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Collagen type II, the main component of total cartilage, is mainly degraded by matrix metalloproteinase13 (MMP-13), which is an important molecule responsible for joint damage in Osteoarthritis (OA).
|
25450366 |
2014 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis.
|
22505473 |
2012 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The most recent studies have suggested a role for the TGF-Beta, HtrA1, Ddr2, and Mmp-13 pathway in the degradation of articular cartilage and the development of OA in cho/+ mice.
|
30719872 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
ERRγ overexpression in chondrocytes directly upregulates matrix metalloproteinase (MMP)-3 and MMP13, which are known to play crucial roles in cartilage destruction in OA.
|
29247173 |
2017 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The expression of collagenase 3 in the synovial membrane in RA and OA suggests its involvement in articular tissue degradation.
|
8730110 |
1996 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The expression of OA associated biomarkers namely Matrix metalloproteinase (MMP-13), NOD-, LRR- and pyrin domain-containing 3 (NLRP3) induced by destabilizing the medial meniscus operation (DMM) were also investigated.
|
31407595 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
RESULTS Icariin treatment (mice in the ACLT + ICA group) significantly reduced degeneration of cartilage in OA with increased cartilage thickness, associated with increased expression of collagen type II alpha 1 (COL2A1), decreased chondrocyte hypertrophy, and decreased expression of collagen type X (ColX) and matrix metalloproteinase 13 (MMP13).
|
30244259 |
2018 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Genes that showed increased expression in OA were MMP13, MMP28, and ADAMTS16 (all at P < 0.001), MMP9, MMP16, ADAMTS2, and ADAMTS14 (all at P < 0.01), and MMP2, TIMP3, and ADAMTS12 (all at P < 0.05).
|
14730609 |
2004 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
IL-1β reduced PRG4 expression in OA synoviocytes and rhPRG4 (100 μg/ml) treatment reversed this effect (p < 0.001). rhPRG4 (200 μg/ml) reduced basal gene expression of MMP-1, MMP-3, MMP-13, IL-6, IL-8, and PRG4 in OA synoviocytes, while increasing TIMP-2 and cycloxygenase-2 (COX2) expression (p < 0.001). rhPRG4 (200 μg/ml) reduced IL-1β induction of MMP-1, MMP-3, MMP-9, MMP-13, IL-6, IL-8, and COX2 expression in a CD44-dependent manner (p < 0.001).
|
28482921 |
2017 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Mechanistic data showed that leptin-treated human OA chondrocytes exhibited enhanced production of lysoPCs and expression of autotaxin and catabolic MMP-13.
|
28811491 |
2017 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
TREM-1 expression was consistently increased in a mouse OA model in vivo, and its silencing led to inhibition of matrix metallopeptidase-13 (MMP-13) production, increased collagen type II synthesis and decreased NF-κB signaling.
|
27932245 |
2017 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
These insights may serve as a potential starting point of further experimental validation and structure-based drug design/repurposing of MMP-13 inhibitors for the treatment of OA.
|
31378153 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The overall percentage of non-methylated sites was increased in OA patients (48.6%) compared with controls (20.1%): 20% versus 4% for MMP-13, 81% versus 47% for MMP-9, 57% versus 30% for MMP-3, and 48% versus 0% for ADAMTS-4.
|
16200590 |
2005 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these data demonstrate that SERPINE2 might prevent cartilage catabolism by inhibiting the expression of MMP-13, one of the most relevant collagenases, involved in cartilage breakdown in OA.
|
26305372 |
2015 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Polymerase chain reaction (PCR) results showed that both IL-1β and chemerin reduced the expression of the protective genes in OA (MMP-1, MMP-3, and MMP-13).
|
29949137 |
2018 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Inflammatory cytokines, including IL-1β, and proteinases such as MMP-13 have been implicated in the pathogenesis and progression of OA together with an associated CpG demethylation in their promoters.
|
21219853 |
2011 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
LHGDN |
Joint diseases and matrix metalloproteinases: a role for MMP-13.
|
18289056 |
2008 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Importantly, inflammatory cytokine production was also increased in B cells from the spleen of CD19-TSC1 conditional KO mice, but the OA phenotype was significantly elevated in conditional KO mice after DMM surgery compared with CON mice, as indicated by more severe articular cartilage destruction, increased protein expression of matrix metalloproteinase-13 and mRNA of type X collagen in the articular cartilage, decreased mRNA expression of type II collagen in the articular cartilage, and increased inflammatory cytokines in serum and the synovial membrane.
|
30408629 |
2018 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In contrast MMP-13 was significantly upregulated in the OA cartilage samples (5.3-fold, p<0.003).
|
19103633 |
2010 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Dexamethasone induced the expression of DUSP1 and inhibited the activation of the MAPK pathway and reduced the expression of MMP‑13 and COX‑2 in OA FLSs.
|
28983624 |
2017 |
|
Degenerative polyarthritis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The zinc-ZIP8-MTF1 axis in chondrocytes forms a catabolic cascade that promotes upregulation of the crucial effector matrix-degrading enzymes MMP3, MMP13, and ADAMTS5, thereby leading to osteoarthritis (OA) cartilage destruction.
|
28224461 |
2017 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The aberrant expression of matrix metalloproteinase-13 (MMP-13) plays a vital role in the pathogenesis of OA.
|
27082436 |
2016 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
IAI-HA ameliorated the OA grade and selectively suppressed MMP-13 mRNA in subchondral bone.
|
20886647 |
2011 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The acquisition of a hypertrophic phenotype (producing aberrant type X collagen and catabolic MMP-13 protease) by chondrocytes is well documented and contributes to OA development.
|
30853397 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The expressions of FAS-AS1, MMP1, and MMP13 in osteoarthritis tissues increased significantly, while COL2A1 presented a low expression.
|
29863238 |
2018 |